Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.
about
Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomographyAntipsychotic dosing: found in translationThe development, past achievements, and future directions of brain PETHistory of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophreniaEffects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPATreatment of severe axial tardive dystonia with clozapine: case report and hypothesis.Modeling of PET data in CNS drug discovery and development.The Roles of Dopamine D2 Receptor in the Social Hierarchy of Rodents and PrimatesStructural and functional brain imaging in schizophrenia.Involvement of Basal Ganglia network in motor disabilities induced by typical antipsychoticsClozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs.Drug development, radiolabelled drugs and PET.Classics in Chemical Neuroscience: Aripiprazole.A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride.Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.Measurement error analysis for the determination of dopamine D(2) receptor occupancy using the agonist radioligand [(11)C]MNPA.Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls.Cytochrome P4502D6 genotype does not determine response to clozapine.Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients.Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010.Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution.Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders.Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.Antipsychotics and amotivationDAT imaging in drug-induced and psychogenic parkinsonism.Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor.Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.Positron emission tomography studies of brain receptors.Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.Movement disorders: neurodevelopment and neurobehavioural expression.Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophreniaPET and SPECT imaging in psychiatric disorders.What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas.Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.
P2860
Q24630426-67F8694E-5E1A-4C7A-AF95-C80B75E961FDQ26863343-61AC567F-F012-439C-8EAA-293D8235388CQ27026331-03F06F94-D72E-4E51-B174-81EB4AEA8C9DQ28283494-3C471064-6A27-4B6A-918A-5FDFCB905511Q28484113-5D88D343-4259-4487-B18C-D417F723D34EQ30465809-EE5EEB32-3404-4BE8-BB47-EEEE3901B3BEQ30623699-6E8942D3-9EC8-44E2-8986-CC6719D39038Q30839880-0E76EC3C-A638-44CC-89D3-01DFEC07D87DQ33396727-9A177BBA-9F85-435B-B056-3E91161F3B55Q33480027-11798B2E-89DC-4FBF-BEC5-39728FE4102CQ33653952-50A4043F-4D91-4B1B-9B1D-43E226F04B7BQ33841662-B7A81124-1D89-4E29-9BBF-F01E49479AB3Q33866125-C57A298F-60B2-405A-A766-DCC5FA4CD9FAQ33921841-E90B0DAD-117A-4A9C-B941-5D5FF755A448Q33961404-69253B48-F5F9-4AF3-A5B7-20A885FA7174Q34011162-4C4247C5-68C8-4FCA-9E16-6E5D60B2ACC5Q34170757-F9BD5C1D-1CD7-4C60-A16A-F3FCD2E87623Q34305236-5C284576-49C8-4FCF-825B-65FCDEE420E6Q34347496-814432B4-E063-4365-B032-67253DF2363BQ34373482-67325DC6-60B7-407B-94EF-6E9461C1459DQ34418688-C5455E06-EA89-4C6F-879F-F251F5318D4DQ34540452-3B452927-E3E3-4337-984D-96D09C02FE39Q34590400-331A316E-0135-4DCE-B31D-4EB80A756081Q34897526-5FD62196-E7C4-4535-8923-F2C8C56BC251Q35158156-BF747EFB-3093-4071-90ED-B8646632C89EQ35421296-2A94F931-EF29-4CA0-A91C-C00E935A66DEQ35552939-55EF0488-32CA-4B34-830C-6098EF02E2DEQ35796578-8727D52D-569D-481C-8F8D-D5789942BC57Q36129732-A91C3DF9-27EB-47DC-B863-65F4E6EE880EQ36503237-9A9AE68C-4B74-452E-9B6C-39412E3698FAQ36579965-4FD2646B-94D1-455A-8A28-F49DAD2E54D1Q36615980-145AC37F-0EA4-4C43-9170-998D5DC78002Q36696136-B4655DA6-C538-47E3-ADD3-A60C7E1FAFEAQ36750941-9C2A7E36-3B31-43B2-86FC-67BB251A305AQ36811276-46BC278D-4AE3-4F00-BBD2-FAE76AFF544EQ36820162-23BEE131-8F3C-43AE-AE6B-78C6EFE14606Q36914354-241E5B7B-523E-4820-B24D-44C6999443AFQ36920020-7B5F776D-223B-4831-BCB1-0CF0F2B2D975Q36941951-7D7D5701-97A4-4049-B195-883AE3F2DC34Q37057313-5E9F509D-835A-4F94-9C4A-107B654EA52E
P2860
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Central D2-dopamine receptor o ...... ated with antipsychotic drugs.
@en
Central D2-dopamine receptor o ...... ated with antipsychotic drugs.
@nl
type
label
Central D2-dopamine receptor o ...... ated with antipsychotic drugs.
@en
Central D2-dopamine receptor o ...... ated with antipsychotic drugs.
@nl
prefLabel
Central D2-dopamine receptor o ...... ated with antipsychotic drugs.
@en
Central D2-dopamine receptor o ...... ated with antipsychotic drugs.
@nl
P2093
P921
P1433
P1476
Central D2-dopamine receptor o ...... ated with antipsychotic drugs.
@en
P2093
P356
10.1001/ARCHPSYC.1988.01800250087012
P407
P577
1988-01-01T00:00:00Z